Abstract

PRP(Platelet Rich Plasma) kişinin kendi kanının yüksek hızlı merkez kaç kuvveti ile bileşenlerine ayrılması sonucu oluşan kan ürünüdür. Yönteme göre değişmekle birlikte ortalama trombosit sayısı 3-5 kat artar, yani PRP sınır değerinin üzerinde trombosit içeren plazmadır. PRP bir ilaç değil bir dokudur yani otolog bir greft olması nedeniyle alerjik reaksiyonlar oluşturması veya dışarıdan bir bulaşıcı hastalık taşıyabilmesi çok zordur.PRP hazırlanış tekniği ve sonunda oluşan ürün içeriğine göre sınıflandırılabilir. PRP kullanımındaki asıl amaç, trombositlerin içerdikleri alfa ve dens granürlerinin zengin içeriklerinin ortama tedavi amaçlı salınımının sağlanmasıdır. Sonuç olarak etkileri ve tedavi süreci ile ilgili soru işareti barındıran bu tedavi yöntemi ile ilgili daha fazla çalışma yapılmasına ihtiyaç vardır.

Keywords

• Trombositten Zengin Plazma,Hemostaz,Plazmanın hücresel komponentleri

Platelet Rich Plasma

Abstract

Platelet rich plasma (PRP) is a blood product obtained by centrifuge of blood which contains more thrombocytes than normal plasma. Although this measurement may be effected by given methods, thrombocyte count is approximately 3-5 times higher in PRP than ordinary plasma. PRP is not a drug but an autologous tissue graft and it is unlikely see allergic reactions and transmitted diseases after the procedure. PRPmay be classified according to the preparation technique and the resulting product content. Aim of the PRP therapy is to administer the rich contents of alpha and dens granules contained by platelets to the relevant medium. More comprehensive studies are needed about this specific therapy in order to clear all the question marks about the topic.

Keywords

• Platelet Rich Plasma,Hemostasis,Cellular components of the plasma

References

1. 1. Nguyen RT, Borg-Stein J, McInnis K. Applications of platelet-rich plasma in musculoskeletal and sports medicine: an evidence-based approach. PM&R. 2011;3(3):226-50.
2. 2. Paoloni J, De Vos RJ, Hamilton B, Murrell GA, Orchard J. Platelet-rich plasma treatment for ligament and tendon injuries. Clinical Journal of Sport Medicine. 2011;21(1):37-45.
3. 3. Rees JD, Maffulli N, Cook J. Management of tendinopathy. The American journal of sports medicine. 2009;37(9):1855-67.
4. 4. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. The American journal of sports medicine. 2009;37(11):2259-72.
5. 5. Park JE, Barbul A. Understanding the role of immune regulation in wound healing. The American Journal of Surgery. 2004;187(5):S11-S6.
6. 6. Siegel A, Lüscher E. Non-identity of the α-granules of human blood platelets with typical lysosomes. Nature. 1967;215(5102):745.
7. 7. Maynard D, Heijnen H, Horne M, White J, Gahl W. Proteomic analysis of platelet α‐granules using mass spectrometry. Journal of Thrombosis and Haemostasis. 2007;5(9):1945-55.
8. 8. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets. 2001;12(5):261-73.

9. 9. Sonnleitner D, Huemer P, Sullivan DY. A simplified technique for producing platelet-rich plasma and platelet concentrate for intraoral bone grafting techniques: a technical note. International Journal of Oral & Maxillofacial Implants. 2000;15(6).
10. 10. Khan KM, Cook JL, Bonar F, Harcourt P, Åstrom M. Histopathology of common tendinopathies. Sports Medicine. 1999;27(6):393-408.
11. 11. de Mos M, van der Windt AE, Jahr H, van Schie HT, Weinans H, Verhaar JA, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. The American journal of sports medicine. 2008;36(6):1171-8.
12. 12. Yıldız C, Özgürtaş T. Trombositten zengin plazma.
13. 13. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Current reviews in musculoskeletal medicine. 2008;1(3-4):165-74.
14. 14. Breen A, O'Brien T, Pandit A. Fibrin as a delivery system for therapeutic drugs and biomolecules. Tissue Engineering Part B: Reviews. 2009;15(2):201-14.
15. 15. Catelas I, Dwyer JF, Helgerson S. Controlled release of bioactive transforming growth factor beta-1 from fibrin gels in vitro. Tissue Engineering Part C: Methods. 2008;14(2):119-28.
16. 16. Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunité en paro-implantologie: le PRF. Implantodontie. 2001;42(55):e62.
17. 17. Prakash S, Thakur A. Platelet concentrates: past, present and future. Journal of maxillofacial and oral surgery. 2011;10(1):45-9.
18. 18. Jain A, Bedi RK, Mittal K. Platelet-rich plasma therapy: a novel application in regenerative medicine. Asian journal of transfusion science. 2015;9(2):113.